Webcasts: EHS Rome 2009 Symposium

Presented on Friday, February 27 • Rome, Italy
In association with the 11th European Haemovigilance Seminar (EHS)


Speaker Videos

Laurence Corash, M.D.(see bio below)
Experience with an Active Haemovigilance Program: Analysis of 35,000 Transfusions with Pathogen Inactivated Components
Jean Claude Osselaer, MD, JD (see bio below)
Patient Outcomes Before and After Implementation
of Pathogen Inactivation: A Six Year Experience
Questions and Answers
line
Speaker Bios

corash Laurence Corash, M.D.
Senior Vice President for Medical Affairs and Chief Medical Officer of Cerus Corporation; and Professor of Laboratory Medicine at the University of California, San Francisco.

Dr. Corash graduated from New York University School of Medicine and completed Internal Medicine training at Bellevue Hospital, New York, NY. From 1971 to 1973 he was a Research Associate at the National Institute of Child Health and Human Development (NICHD), Bethesda, MD; and completed training in Hematology and Hematopathology at the National Institutes of Health (NIH), Clinical Center, Bethedsa,MD. From 1977 to 1981 he served as Assistant Chief, Hematology Service, Clinical Center, NIH. From 1982 to 1997 Dr. Corash was Chief of the Hematology Laboratory Service at the University of California, San Francisco and a member of the faculty in Medicine and Laboratory Medicine. His research activities include blood cell aging and technology for inactivation of infectious pathogens in blood components. He has published more than 150 basic research papers in the broad field of hematology and transfusion medicine. Over the past 10 years, Dr. Corash has directed a research team in the development of technology for the inactivation of pathogens in labile blood components. The system for preparation of platelets received European Community CE Mark registration in 2002.

 

osselaer Jean Claude Osselaer, MD, JD
Transfusion Center, Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium

Dr Osselaer has been the Head of the Apheresis Unit, Blood Bank and Tissue- Typing Laboratory at the Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium since 1992. In 1999, he also became Medical Director of the newly created Blood Transfusion Centre (BTC) of Mont-Godinne, and combines this role with Medical Directorship of the BTC of Charleroi. Dr Osselaer graduated as MD at the Université Catholique de Louvain in 1982, and trained in haematology and clinical pathology. He is also Master in Law, and holds a special degree in Insurance Law and Forensic Medicine. He is a member of several international associations in the field of transfusion and apheresis.

 

 
Untitled Document